High dose testosterone for Prostate Cancer
Phase-Based Progress Estimates
Effectiveness
Safety
Prostate Cancer+1 More
High dose testosterone - DrugEligibility
18+
Male
What conditions do you have?
Select
Eligibility
18+
Male
What conditions do you have?
Select
Study Summary
This trial will test whether intermittent high-dose testosterone therapy can shrink tumors in men with DNA repair deficiency.
Eligible Conditions
- Prostate Cancer
- Malignant Neoplasms
Treatment Effectiveness
Effectiveness Progress
Other trials for Prostate Cancer
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 12 weeks
12 weeks
PSA response
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Prostate Cancer
Trial Design
3 Treatment Groups
CHEK2
1 of 3
CDK12
1 of 3
ATM
1 of 3
Experimental Treatment
51 Total Participants · 3 Treatment Groups
Primary Treatment: High dose testosterone · No Placebo Group · Phase 2
CHEK2
Drug
Experimental Group · 1 Intervention: High dose testosterone · Intervention Types: DrugCDK12
Drug
Experimental Group · 1 Intervention: High dose testosterone · Intervention Types: DrugATM
Drug
Experimental Group · 1 Intervention: High dose testosterone · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,473 Previous Clinical Trials
2,741,705 Total Patients Enrolled
12 Trials studying Prostate Cancer
3,691 Patients Enrolled for Prostate Cancer
Robert B. Montgomery, MDPrincipal InvestigatorVA Puget Sound Health Care System Seattle Division, Seattle, WA
3 Previous Clinical Trials
142 Total Patients Enrolled
1 Trials studying Prostate Cancer
14 Patients Enrolled for Prostate Cancer
Eligibility Criteria
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have signed an informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information.
You have had an orchiectomy and are receiving gonadal androgen deprivation therapy with GnRH analogues, antagonists or orchiectomy.
Evaluable disease progression by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria.
Presence of metastatic disease on bone or CT scan.
You have a histologically or cytologically confirmed adenocarcinoma of the prostate.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Washington | 100.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| VA Puget Sound Health Care System Seattle Division, Seattle, WA | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments